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Differences in the intestinal 
microbiome of healthy children 
and patients with newly diagnosed 
Crohn’s disease
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Agnieszka H. Ludwig-Słomczyńska3, Paweł P. Wołkow  3 & Krzysztof fyderek1
The aetiology of inflammatory bowel diseases (IBD) seems to be strongly connected to changes in the 
enteral microbiome. The dysbiosis pattern seen in Crohn’s disease (CD) differs among published studies 
depending on patients’ age, disease phenotype and microbiome research methods. The aims was to 
investigate microbiome in treatment-naive paediatric patients to get an insight into its structure at 
the early stage of the disease in comparison to healthy. Stool samples were obtained from controls 
and newly diagnosed patients prior to any intervention. Microbiota was analysed by 16SrRNAnext-
generation-sequencing (NGS). Differences in the within-sample phylotype richness and evenness (alpha 
diversity) were detected between controls and patients. Statistically significant dissimilarities between 
samples were present for all used metrics. We also found a significant increase in the abundance of OTUs 
of the Enterococcus genus and reduction in, among others, Bifidobacterium (B. adolescentis), Roseburia 
(R.faecis), Faecalibacterium (F. prausnitzii), Gemmiger (G. formicilis), Ruminococcus (R. bromii) and 
Veillonellaceae (Dialister). Moreover, differences in alpha and beta diversities in respect to calprotectin 
and PCDAI were observed: patients with calprotectin <100 µg/g and with PCDAI below 10 points vs 
those with calprotectin >100 µg/g and mild (10–27.7 points), moderate (27.5–40 points) or severe (>40 
points) CD disease activity had higher richness and diversity of gut microbiota. The results of our study 
highlight reduced diversity and dysbiosis at the earliest stage of the disease. Microbial imbalance and 
low abundance of butyrate-producing bacteria, including Bifidobacterium adolescentis, may suggest 
benefits of microbial modification therapy.
Crohn’s disease (CD) belongs to the group of chronic inflammatory bowel disorders (IBD) that may affect any 
part of the gastrointestinal tract (GI). Intensity and range of lesions may change over time; inflammation usually 
presents a non-continuous pattern and affects all layers of the intestinal wall. In the past two decades, all devel-
oped countries have experienced a steady increase in the prevalence of CD in children1, with declining age at 
presentation and intensifying activity2. The underlying cause of this phenomenon is unknown; however, one of 
the possible reasons is seen in the ongoing civilization changes taking place in the environment. These changes 
undoubtedly affect the microbiome, which plays important role in the proper functioning of the intestines. With 
certainty, the microbiome helps to maintain appropriate function of the gut and plays an important role in vita-
min production, development of the immune system, epithelial homeostasis and metabolite production, all of 
which strongly contribute to enhancement of gut barrier function3–5. It is difficult to define a healthy gut microbi-
ome as it varies depending on age, environment, or diet, but it should generally be characterized by diversity and 
stability and fulfil its metabolic function6. Numerous studies, both on animal models and humans, have shown 
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that alterations in the gastrointestinal microbiome together with genetic susceptibility and environmental factors 
are important in initiating the inflammatory process mainly via an abnormal immune response7–9.
Exploration of bacterial diversity using culture-independent techniques enabled a better evaluation of 
the composition of gut microbiota. Changes in the microbiome of CD patients imply both bacterial richness 
and diversity. The most frequently observed changes are decrease in Bacteroides and Firmicutes and increase 
in Actinobacteria and Gammaproteobacteria10. CD patients’ intestinal microbiome was shown to be poor in 
Faecalibacterium prausnitzii, commensal bacteria with anti-inflammatory properties11, Roseburia intestinalis and 
other butyrate-producing bacteria12.
So far, only a few studies assessing the microbiome in patients with IBD focused on children. The majority 
of published papers concerned small cohorts which were heterogeneous in terms of diagnosis and phenotype 
of IBD, treatment and duration of the disease. Also, the results of two big paediatric CD studies from North 
America12 and Netherland13 are not fully compatible.
The aim of this study was to investigate microbiome composition in newly diagnosed, untreated children with 
CD compared to their healthy peers. We also wanted to assess whether the change in the microbiome correlates 
with the clinical activity of CD and the biochemical indicators of inflammation.
Methods
Patients. Ethical approval. All procedures were performed in studies involving human participants were in 
accordance with the ethical standards of the institutional committee Jagiellonian University Ethics Committee 
(decision number: 122.6120.68.2015) and with the 1964 Helsinki declaration and its later amendments or com-
parable ethical standards. All experimental protocols were approved by Jagiellonian University Ethics Committee 
in Krakow, Poland.
Informed consent was signed by patients’ parents or legal guardians if they are under 18 years of age. If the 
patient is above 16 years old, then in addition to the consent of the parents or legal guardians, its written consent 
to participate in the study was also obtained.
This single-centre prospective study was performed at University Children’s Hospital in Kraków, Poland. 
Newly diagnosed children and adolescents with CD, aged 2 to 18 years, were enrolled in the study group. The 
diagnosis was based on clinical manifestation, biochemical, endoscopic and histopathological studies, as well as 
radiological tests in accordance with revised Porto criteria14. Morphology and biochemical tests including ESR 
(erythrocyte sedimentation rate), C-reactive protein (CRP) and faecal calprotectin were checked at admission. 
The Simple Endoscopic Score for Crohn’s Disease (SES-CD) was assessed during a diagnostic upper gastroscopy 
and ileocolonoscopy. The phenotype of CD was assessed according to the Paris criteria15. Details for Paediatric 
Crohn’s Disease Activity Index (PCDAI) were collected at admission.
The exclusion criteria were: patients below 2 or above 18 years of age; treatment with antibiotics and/or probiotics 
during the period of 3 months before collecting the stool sample; confirmed infections of the gastrointestinal tract; 
isolated perianal disease; and lack of consent to participate in the study. Samples in the study group were collected at 
admission to the hospital prior to any medical or therapeutic intervention. Faecal calprotectin and all clinical data 
necessary to assess clinical activity were collected before the commencement of any therapeutic intervention.
The control group consisted of healthy non-hospitalized children (HC – healthy controls) who didn’t meet the 
exclusion criteria. Their stool samples were collected at home into sterile stool containers, kept refrigerated and 
transported in cool bags to the laboratory. All stool samples were stored at −80 °C.
Laboratory procedures. DNA extraction from the faecal samples. A detailed DNA isolation protocol was 
presented in our team’s previous studies16. The frozen samples were thawed, precisely weighed (about 0.1 g of 
stool sample was used) and homogenized in 0.1 ml of saline. After lysis of bacterial and fungal cells with lysozyme 
(Sigma-Aldrich, Poznań, Poland) (1 mg/ml) and lysostaphin (Sigma-Aldrich, Poznań, Poland) (0.1 mg/ml), sam-
ples were incubated at 37 °C for 20 min. Next, 200 μl 75 mM NaOH (Avantor Performance Materials, Gliwice, 
Poland) was added and samples were incubated at 95 °C for 10 min. After incubation, probes were microcentri-
fuged (12 000 rpm, 10 min), supernatants were removed, and pellets were resuspended in 500 μl buffer supple-
mented with β-mercaptoethanol (Sigma-Aldrich, Poznań, Poland). For each sample, lyticase (Sigma-Aldrich, 
Poznań, Poland) was added (0.1 mg/ml). Probes were incubated at 37 °C for at least 30 min and microcentrifuged 
(12 000 rpm, 10 min). The next steps of DNA extraction were carried out according to Genomic Mini AX Stool 
Spin Kit (A&A Biotechnology, Gdańsk, Poland) procedure.
DNA concentration and purity was controlled spectrophotometrically using a NanoDrop apparatus (Thermo 
Fisher Scientific).
16S library preparation. An amplicon library was created. Amplicons of the selected V3-V4 16 S rRNA gene regions 
for each sample studied were prepared using following primers with adapters17: (F) 5′TCGTCGGCAGCGTCA 
GATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 3′ (R)5′ GTCTCGTGGGCTCGGAGATGTGT 
ATAAGAGACAGGACTACHVGGGTATCTAATCC 3′. PCR product was purified using Agencourt AMPure XP 
(BeckmanCoulterGenomics). Next, library indexing was performed applying Nextera XT Index Kit (Illumina 
San Diego, California, United States) and one more purification was done. Libraries were fluorescently quantified 
(Quant-iT™ PicoGreen™ dsDNA Assay Kit - Thermo Fisher Scientific) and normalized to 10 nM and pooled in 
Eppendorf tube. According to the Illumina protocol for a 2 × 300 cycle run; 10 pM library concentration; 30% 
PhiX sequencing control V3 for MiSeq high-throughput sequencer were used (Illumina, San Diego, California, 
United States): http://support.illumina.com/content/dam/illuminasupport/documents/documentation/chemis-
try_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf. The sequencing procedure was 
performed at the Centre for Medical Genomics OMICRON, Jagiellonian University Medical College.
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Sequencing data analysis and statistical analysis. The samples were processed and analysed using 
the Quantitative Insights Into Microbial Ecology (QIIME2, version 2018.11)18 custom pipeline. All following 
procedures in this section were conducted in the QIIME2 environment (using QIIME2 plugins). Demultiplexed 
paired-end reads from MiSeq (2 × 300 bp) were trimmed to remove primers and poor quality bases with 
Cutadapt19. The trimmed sequences were denoised and joined with DADA220. Then open-reference clustering 
of features21 and reference-based chimera filtering were performed using vsearch22 and the Greengenes data-
base at 99% similarity23. The generated operational taxonomic units (OTUs) were assigned to taxonomy using a 
pre-trained Naive Bayes classifier24.
The classifier was trained on the region of the target sequences that were sequenced. Briefly, we extracted 
sequences from Greengenes 13.8, 99% OTUs with locus-specific sequences from V3-V4 Illumina 16 S Amplicon 
Primers. Based on the taxonomy generated, we filtered our feature-table to include only assigned reads of the king-
dom Bacteria and to remove singleton features and elements with fewer than 10 reads. The filtered feature-table 
was used to generate the tree for phylogenetic diversity analyses. Briefly, we de novo aligned sequences using 
MAFFT25 and masked highly variable positions26. Then, we applied FastTree27 to generate an unrooted phyloge-
netic tree from masked alignment. In the final step, we rooted the tree at the midpoint of the longest tip-to-tip 
distance in the unrooted tree. Rarefaction curve analysis of the data obtained was used to estimate the complete-
ness of microbial communities sampling. Subsequently, we computed several alpha (Shannon’s diversity index, 
observed OTUs, Faith’s Phylogenetic Diversity, Pielou’s evenness) and beta diversity metrics (Jaccard distance, 
Bray–Curtis distance, unweighted UniFrac distance, weighted UniFrac distance and generated principal coor-
dinates analysis PCoA) plot using Emperor28 for each of the beta diversity metrics. Group significance between 
alpha and beta diversity indexes was calculated with QIIME2 plugins using the Kruskal–Wallis test and per-
mutational multivariate analysis of variance (PERMANOVA), respectively. Correlations with alpha diversity 
indexes were calculated with QIIME2 plugin using the Spearman correlation. Differential abundance between 
groups on each taxonomic level was tested with ANCOM29, with a taxa-wise correction for multiple testing. The 
ANCOM procedure compares the relative abundance of a taxon between two groups, by performing statistical 
tests on data transformed by an additive log-ratio (Aitchison’s log-ratio) of the abundance of given taxon versus 
the abundance of all other taxa, individually. The W-value generated by ANCOM method is a count of a number 
of sub-hypotheses (Aitchison’s log-ratio) that were detected to be significantly different across tested groups for a 
given taxon. The significance of a test for a given taxon is determined by the Benjamini-Hochberg correction that 
controls for False Discovery Rate (FDR) at 0.05.
Results
A total of 82 children and adolescents aged 2–18 years (mean 148.52 months; SD = 41.09) were included in the 
study. General characteristics of participants are given in Table 1. None of the patients presented with isolated L4a 
or L4b location or exclusive perianal disease. In two-thirds of the patients, initial disease activity (according to 
PCDAI) was assessed as mild to moderate. The endoscopic score (SES-CD) was 17.3 (SD = 8.04).
Quality of DNA isolates. Isolates with a concentration of >100 ng/µl and a purity ratio A260/A280 > 1.7 were 
used to prepare libraries and sequencing.
16 S rRNA V3-V4 region sequencing results. After clustering, removal of chimeras and filtering, 
2,008,883 sequences from 82 samples with 619 OTUs were obtained. Percentage of annotated OTUs on the phy-
lum (L2), class (L3), order (L4), family (L5), genus (L6), and species (L7) level 100%, 100%, 98.8%, 93.7%, 72.2% 
and 24.9% OTUs, respectively. The median frequency was 23,662 with IQR 15,919–31,744. Based on the rare-
faction curve, the alpha and beta diversity metrics were calculated on a rarefied frequency-feature table with a 
minimum number of 4252 sequences per sample. One sample was excluded from diversity analyses due to low 
read count.
Differences in the within-sample phylotype richness and evenness (alpha diversity) were detected between 
controls and CD patients. Shannon’s diversity index (p < 0.001), observed OTUs (p = 0.003), Faith’s Phylogenetic 
Diversity (p = 0.049) and Pielou’s evenness (p < 0.001), were statistically different between controls and CD 
patients (Fig. 1).
Statistically significant dissimilarities between samples (beta diversity) were seen in all distance metrics: 
Jaccard distance (p = 0.001), Bray–Curtis distance (p = 0.001) unweighted UniFrac distance (p = 0.001), weighted 
UniFrac distance (p = 0.002). PCoA 2D plots from beta diversities are presented in Fig. 2.
Relative abundance of the top bacteria at phylum level (L2) in control and CD groups were: Firmicutes 
(77.03% vs 68.75%), Actinobacteria (17.17% vs 20.61%), Bacteroidetes (2.74% vs 4.01%), Verrucomicrobia 
(2.12% vs 3.56%) and Proteobacteria (0.88% vs 2.63%), respectively.
Top bacteria at class level (L3) in control and CD groups were: Clostridia (71.22% vs 36.80%), Bacilli (3.74% vs 
25.91%), Actinobacteria (13.77% vs 16.15%), Erysipelotrichia (2.08% vs 6.03%), Coriobacteriia (3.41% vs 4.45%), 
Bacteroidia (2.74% vs 4.01%), Verrucomicrobiae (2.12% vs 3.56%) and Gammaproteobacteria (0.88% vs 2.49%), 
respectively.
Composition of the bacterial community at the genus level (L6) for control and CD samples are shown in 
Fig. 3.
ANCOM analysis at the genus (L6) and species (L7) levels showed that there are 11 genera (Table 2 and 
Fig. 4A) and 17 species (Table 3 and Fig. 4B) differently expressed between controls and CD patients. The analyti-
cal method allowed to determine the exact species names for only 6 of them. We have found a significant increase 
in the abundance of OTUs of the genus Enterococcus and a statistically significant reduction in Bifidobacterium 
(B. adolescentis), Adlercreutzia, Clostridium (C. celatum), Coprococcus, Roseburia (R. faecis), Faecalibacterium (F. 
prausnitzii), Gemmiger (G. formicilis), Ruminococcus (R. bromii) and Veillonellaceae (Dialister).
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Correlation of microbiome structure and clinical parameters. Alpha and beta diversity does not cor-
relate with most of the clinical parameters. We did not find associations between microbiome structure and Paris 
scale parameters, SES-CD and PCDAI or infectious biochemical parameters like ESR and CRP, serum iron and 
albumin level. However, we have observed differences in alpha (Fig. 5) and beta diversities (Fig. 6) with respect 
to calprotectin: patients with calprotectin <100 µg/g (n = 8) have higher richness and diversity of gut microbiota 
than patients with calprotectin levels between 100 µg/g and 1800 µg/g (n = 21) and above 1800 µg/g (n = 33). We 
also observed some microbiome change associations with PCDAI of less than
10 points (5 patients) vs those with mild (10–27.5 points; 21 patients), moderate (>27.5–39 points, 17 
patients) and severe (>40 points; 21 patients) CD disease activity (Supplementary Fig. S1 online).
Discussion
In our cohort of treatment-naïve CD patients, a reduction in microbiota diversity and richness compared to 
healthy controls was shown. We found that 11 genera and 17 species differed significantly between CD patients 
and HC. The respective alteration was observed in OTUs belonging to Actinobacteria and Firmicutes.
A significant increase in the abundance of OTUs of the genus Enterococcus in our paediatric CD patients 
was consistent with the findings of other authors30,31. In our cohort, we also found a significant reduction in 
the abundance of OTUs of the genus (and species): Bifidobacterium (B. adolescentis), Adlercreutzia, Clostridium 
(C. celatum), Coprococcus, Roseburia (R. faecis), Faecalibacterium (F. prausnitzii), Gemmiger (G. formicilis), 
Ruminococcus (R. bromii) and Veillonellaceae (Dialister). Similar observations, i.e. a gain in Enterococcus and 
significant decrease in bacteria producing short-chain fatty acids (SCFA) like Coprococcus, Faecalibacterium, 
Roseburia, Ruminococcus, Anaerostipes, Blautia, Lachnospira and Sutterella were reported by others, both in pae-
diatric12,32–34 as well as adult9,35 CD patients.
Although numerous studies confirm that microbiome in IBD patients is different in terms of quantity and 
quality compared to healthy people, based on the research carried out so far, it has not been possible to determine 
a single strain of bacterial species responsible for causing inflammation associated with CD. Probably, a widely 
understood change in the microbiome at various taxonomic levels and also in a different anatomic location in 
the GI tract plays a pathogenic role. Similar to our observation, in adult CD patients, Joossens et al. reported 
a decrease in Faecalibacterium prausnitzii, Bifidobacterium adolescentis, Dialister and did not characterize 
Crohn’s disease 
patients (CD) (n = 64)
Healthy controls 
(HC) (n = 18)
Sex: male 61% (39/64) 44% (8/18)
Age (months; SD) 151.41 (SD = 42.41) 138.28 (SD = 35.16)
Height (cm; SD) 150.77 (SD = 20.6) 146.67 (SD = 20.52)
Weight (kg, SD) 38.32 (SD = 13.79) 41.75 (SD = 17.37)
BMI 16.24 (SD = 2.65) 18.3 (SD = 3.49)
Disease distribution by Paris classification: (number of patients)
A1a 13
A1b 47
A2 4
L1 2
L2 8
L3 15
L4aL1 10
L4aL2 11
L4aL3 17
B1 41
B2 20
B2 B3 3
G0 40
G1 24
p 1
PCDAI: 31.48 (SD = 15.44)
≤40 (mild and moderate) 43
>40 (severe) 21
Table 1. General characteristics of participants. CD – Crohn’s disease, m – months, SD – standard deviation, 
PCDAI – Paediatric Crohn’s Disease Activity Index. Paris classification: age: A1a: 0–10 y, A1b: 10–17 y, A2: 
17–40 y; location: L1 – distal 1/3 ileum and/or limited cecal disease; L2 – colonic; L3 – ileocolonic; L4a – upper 
disease proximal to ligament of Treitz; L4b – upper disease distal to ligament of Treitz and proximal to distal 
1/3 ileum, behaviour: B1 – non-structuring non-penetrating; B2 – structuring; B3 – penetrating; B2B3 – both 
penetrating and structuring disease either at the same or different times; p – perianal disease modifier; growth: 
G0 – no evidence; G1 – growth delay.
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Figure 1. Alpha diversity analysis of control and CD patients. Within-sample diversity measured by Shannon 
index (A), observed OTUs (B), Faith’s phylogenetic diversity (C) and Pielou’s measure of species evenness (D). 
Kruskal-Wallis test was performed to analyse statistical significance.
Figure 2. PCoA 2D plots of beta diversity analysis of control and CD patients. Between-sample dissimilarities 
were measured by Jaccard distances (A), Bray-Curtis distance (B), unweighted UniFrac distances (C) and 
weighted UniFrac distances (D). Permutational multivariate analysis of variance (PERMANOVA) was 
performed to analyse statistical significance.
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Clostridium species, and there was an increase in Ruminococcus gnavus. Their study cohort consisted of already 
diagnosed and treated patients35. The presence of similar changes in the bacterial flora in children and adults 
indicates the existence of a definite age-independent pattern for changing the microbiome in CD patients. What is 
more, the dysbiosis existing in treated patients may suggest ongoing inflammation and incomplete response to the 
treatment or shows that this type of dysbiosis is permanent and not related to the treatment or illness activity. In 
the latter case, bacteria are rather indicators than mediators of IBD. This is in concordance with the observation of 
Vrakas et al., who found changes in the microbiome characteristic for CD in both active as in-active individuals36. 
On the other hand, O’Brien et al. didn’t find any imbalance or reduced microbial diversity in patients whose 
only endoscopic lesions were aphthous ulcers. The authors suggest that dysbiosis improves when patients are in 
remission37.
Results of published studies are inconsistent and difficult to compare as the research differs not only in terms of 
selection of the study groups, the age of patients, disease duration and methods of treatment, but also the method-
ology applied. Depending on study design, luminal (stool samples)9,32,33,35,38,39 or/and mucosal (biopsy)12,36,37,40,41 
microbial environment were investigated in IBD patients. Prevalence of one material over another is under dis-
cussion, although it seems that mucosal biopsy gives deeper insight into microbial alteration42. On the other hand, 
obtaining stool samples is easier, non-invasive and repeatable even in short periods of time.
Studies on the microbiome in children are still relatively few and most often concern small groups of patients. 
In the big cohort study of treatment-naïve new-onset paediatric CD patients, the imbalance was shown only in 
Figure 3. Composition of the bacterial community at the genus (L6) level for control and CD samples. Relative 
abundance of top 20 genera are shown.
Control CD W-statistic value
clr mean 
difference
g__Adlercreutzia 0.19% 0.04% 106 −2.02
g__Enterococcus 0.29% 17.62% 140 4.47
o__Clostridiales;__;__ 11.48% 3.55% 109 −3.35
f__Clostridiaceae;g__ 3.37% 0.03% 118 −3.57
g__Clostridium 2.80% 0.50% 111 −3.05
f__Lachnospiraceae;__ 1.10% 0.58% 108 −2.72
g__Coprococcus 8.93% 3.55% 107 −3.06
g__Roseburia 1.94% 0.29% 116 −3.43
g__Faecalibacterium 2,67% 0,49% 109 −2.83
g__Gemmiger 7.03% 3.88% 105 −3.23
g__Ruminococcus 5,94% 1,06% 115 −3.08
Table 2. Statistically significant ANCOM results at genus level. Relative abundance across all samples or 
features within a group were summed. clr - centered log-ratio.
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the microbiome obtained from biopsy, not from stool samples12. Also, Douglas et al. state that microbiome from 
stool samples differs drastically when compared with mucosa samples41. In contrast, our results are in agreement 
with the results of those authors who were able to confirm imbalance both in numbers as well as in biodiversity 
in faecal microbiome13,33. In our study, we assessed a quite large, homogeneous group of patients and we decided 
to use a non-invasive method (stool samples), which allowed us to include fully healthy children who did not 
require a colonoscopy to HC group. Regardless of whether the microbiome is assessed in stool or biopsy samples, 
the results obtained by different authors show some differences. For example, what is intriguing, Hansen et al., 
in biopsies, showed an increase in F. prausnitzii in de-novo diagnosed paediatric CD40. Generally F. prausnitzii 
is an essential component of the intestinal microbiome of healthy people. Numerous studies indicate that this 
bacterium can be considered a microbiological marker of inflammation in the gastrointestinal tract43,44. We, as 
many authors mentioned, confirmed lack of F. prausnitzii in the stool of CD patients. The question is whether the 
reduction in F. prausnitzii in the stool may precede its reduction in the mucous membrane, the natural habitat for 
this gram-positive, anaerobic species, or conflicting results follow the method used. Perhaps to answer this ques-
tion it would be necessary to compare the biopsy results with those of stool in the same patient group.Another 
study indicates that IBD dysbiosis was mainly characterized by decreased abundance of Alistipes finegoldii and 
Alistipes putredinis, members of the core microbiota of healthy state. The authors did not observe large differences 
in the abundance of F. prausnitzii13. In our study, we have found a statistically significant decline in F. prausnitzii 
abundance while Alistipes finegoldii and Alistipes putredinis, although present, did not show significant differences 
between disease and healthy state. In general, however, we support the authors’ opinion that IBD microbiome is 
characterized more by diminishing abundance of certain bacterial species than by an increase in pathogens. In 
the study conducted by Kugathasan et al., 14 genera associated with CD were identified with the largest increase 
Figure 4. Volcano plots of differentially expressed OTUs between control and CD patients at genus (A) and 
species (B) levels. ANCOM analysis was performed to analyse a statistical significance. Statistically significant 
OTUs are represented as red rounds.
CONTROL CD
W-statistic 
value
clr mean 
difference
Bifidobacterium adolescentis 6.56% 0.67% 151 −2.98
f__Coriobacteriaceae;g__;s__ 0.70% 0.90% 146 −2.40
g__Adlercreutzia;s__ 0.19% 0.04% 155 −2.04
g__Enterococcus;s__ 0.29% 17.45% 191 4.34
o__Clostridiales;__;__;__ 0.86% 0.068% 160 −3.37
f__ Clostridiaceae;g__;s__ 3.37% 0.026% 177 −3.589
g__Clostridium;s__ 0.578% 0.14% 139 −2.04
Clostridium celatum 1.42% 0.13% 159 −2.61
f__Lachnospiraceae;__;__ 1.10% 0.58% 162 −2.75
f__Lachnospiraceae;g__;s__ 1.55% 0.10% 144 −2.13
g__Anaerostipes;s__ 0.22% 0.06% 148 −1.83
g__Coprococcus;s__ 8.61% 3.47% 149 −3.00
Roseburia faecis 1.89% 0.27% 172 −3.39
Faecalibacterium prausnitzii 2.67% 0.49% 163 −2.85
Gemmiger formicilis 7.03% 3.89% 157 −3.25
Ruminococcus bromii 4.80% 0.62% 165 −3.07
g__Dialister;s__ 0.92% 0.35% 148 −2.39
Table 3. Statistically significant ANCOM results at species level. Relative abundance across all samples or 
features within a group were summed. clr - centered log-ratio.
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Figure 5. Alpha diversity analysis of control and CD patients with different level of calprotectin. Within-sample 
diversity measured by Shannon index (A), observed OTUs (B), Faith’s phylogenetic diversity (C) and Pielou’s 
measure of species evenness (D). Kruskal-Wallis with Post-hoc was performed to analyse statistical significance. 
Statistically significant values between control and other groups were represented as “#”. Statistically significant 
values between PCDAI < 10 group and with other groups: mild (10–27.5 points; 21 patients), moderate (>27.5–
39 points, 17 patients) and severe (>40 points; 21 patients) CD disease activity (Supplementary Fig. S1 online) 
were represented as “*”.
Figure 6. PCoA 2D plots of beta diversity analysis of control and CD patients with different level of 
calprotectin. Between-sample dissimilarities were measured by Jaccard distances (A), Bray-Curtis distance (B), 
unweighted UniFrac distances (C) and weighted UniFrac distances (D).
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in Aggregatibacter and the greatest decrease in Roseburia and SCFA-producing bacteria34. Gevers et al. underline 
the role of Fusobacterium as a biomarker of inflammation in IBD12 and Douglas et al. states that Desuflovibrio 
and Akkermansia muciniphila are the IBD most informative genera41. Our results support the theory that lack 
of F. prausnitzii and B. adolescentis in the stool can serve, although not always with statistical significance, as a 
biomarker signal of dysbiosis typical for CD13,33. Pascal et al. have attempted to establish microbial biomarkers of 
CD and the results obtained by them give hope for the creation of a promising non-invasive diagnostic method 
in CD suspected patients with nonspecific signs of disease39. We have also observed a decrease in the abundance 
of Roseburia in newly diagnosed children, which may contribute to the suggestion of Imhann et al. that these 
changes can precede the onset of IBD9.
Environment, diet and genetic background seem to be key players in the creation of gut microbiota. Ashton 
et al. observed compositional changes in microbiota between individual patients as well as differences between 
patients and healthy controls45. Interestingly, the microbiome in untreated patients and their healthy siblings 
showed some similarity which may confirm the role of environment and dietary habits in microbiome com-
position. On the other hand, Ijaz et al. showed that the microbiome in healthy adult relatives of paediatric CD 
patients is more similar to the microbiome in healthy adult controls46. Joossens et al. did not reveal the same type 
of dysbiosis as in CD patients either in unaffected relatives or healthy controls35. Those two studies may confirm 
that alteration in microbiome composition is related more strongly to the illness itself than to genetic background 
and nutritional habits or is related to some other environmental factors.
Assessment of microbiome composition in treatment-naïve paediatric population gives an opportunity to 
determine changes unaffected by treatment and accompanying health problems. One of the purposes of our study 
was to find out the correlation between microbiome, clinical activity and manifestation of CD and the biochem-
ical indicators of inflammation. Kugathasan et al. have attempted to attribute changes in the microbiome to the 
location of illness in the GI tract and typical complications, i.e. stenosis and fissures. They suggest a correlation 
between Ruminococcus with structuring complication and Veillonella with penetrating form34. As for localization, 
Pascal et al. detected increased abundance of Enterococcus faecalis when CD was localized in ileum compared 
with ileocolon location39. We did not find a similar relationship in our patients.
The study investigating microbiome in treatment-naïve new-onset paediatric CD patients confirmed that 
alteration in abundance of several taxa and diminished richness of taxa was related to the intensity of inflamma-
tion12. We have also observed a decrease in alpha and beta diversities with an increased level of faecal calprotectin 
and higher disease activity index (PCDAI). This indicates a link between dysbiosis and inflammation of the gas-
trointestinal tract. The question is whether dysbiosis is the direct cause of inflammation or rather its consequence. 
Perhaps, apart from the trigger factor, the mechanism of a vicious circle works: persistent inflammation deep-
ens dysbiosis and vice versa. Similarly to other authors, we show no change in the diversity of the microbiome 
depending on other disease activity and biochemical markers (CRP, ESR)9. Those parameters were not statistically 
significantly associated with changes in microbiome. This in turn may indicate that, taking into account micro-
biom, local inflammation (i.e. located in the gastrointestinal tract and reflected by high calprotectin level) is more 
important than generalised inflammatory status.
The strengths of this study are a homogeneous group of patients, consistent data and sample collection. The 
main weakness, in our opinion, is the lack of mucosa biopsies for assessment of mucosa-associated microbiome. 
Additional study limitation is lack of a mock-community or spike-in positive control, which could accurately 
characterized performance of our metagenomic workflow, and could be used as a reliable reference against which 
to standardize sample between different experiments and studies.
Conclusion
Our work contributes to the data helping understand intestinal dysbiosis in new-onset, treatment-naive paedi-
atric CD patients.
If the change in intestinal microflora is one of the risk factors for the development and / or persistence of 
inflammation in IBD, then the microbiome-oriented treatment should be a component of the therapeutic goals. 
Such treatment methods as antibiotics, pro- and prebiotics as well as faecal microbiota transplant can be taken 
into account. Furthermore, considering the relationship between microbiota and genetic predisposition, the use-
fulness of a microbiome-based preventive treatment in high-risk groups may be considered.
Consistent data confirming low abundance and diversity of Bifidobacterium in CD patients suggest that fur-
ther studies are needed to answer the question whether it is possible to use Bifidobacterium adolescentis as a 
probiotic.
Although studies of the faecal stream may face limitations in detecting microbes associated with the mucus 
layer and, thus, those more directly involved in disease initiation and perpetuation, the application of this method 
is far less invasive and allows multiple and reproducible material collection which makes it possible to monitor 
disease progression.
It is still an open field and active research area for investigation of the best therapeutic strategies to successfully 
manipulate microbiota in CD patients.
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